Key result
CHF 2363 exerted potent antiaggregating and vasorelaxant activity via nitric oxide release and increased cyclic GMP levels, with no in vitro cross-tolerance with glyceryl trinitrate.
Why the study?
Does CHF 2363 inhibit platelet aggregation and induce vasorelaxation in preclinical models?
Does CHF 2363 inhibit platelet aggregation and induce vasorelaxation in preclinical models?
CHF 2363 is a novel furoxan derivative that acts as a potent NO donor, inhibiting platelet aggregation and inducing vasorelaxation without cross-tolerance to GTN in preclinical models.
Answers are grounded in this paper and cite their sources.
Preclinical activity without GTN cross-tolerance supports human testing of CHF 2363; leaves open clinical efficacy and safety.
The mechanism of action and the pharmacological effects of the new furoxan derivative, CHF 2363 (4-ethoxy-3-phenylsulphonylfuroxan), were investigated. 2. Pre-incubation of CHF 2363 with human platelet-rich plasma produced a concentration-dependent inhibition of the platelet aggregation induced by collagen, adenosine diphosphate (ADP) and platelet activating factor (PAF). The test compound was about 5 times more potent than sodium nitroprusside. 3-Isobutyl-1-methyl-xanthine (IBMX) potentiated the antiaggregating effect of CHF 2363. 3. CHF 2363 was a potent inhibitor of rubbed endothelium rabbit aortic ring contraction induced by noradrenaline. Comparison of IC50 values showed that CHF 2363 was as potent as glyceryl trinitrate (GTN). 4. Increasing concentrations of CHF 2363 elevated platelet guanosine 3':5'-cyclic monophosphate (cyclic GMP) levels. Adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels were unaffected. 5. Oxyhaemoglobin reduced all the pharmacological actions of the test compound. Moreover, CHF 2363 concentration-dependently released nitric oxide (NO) in platelet-rich plasma. The NO release was correlated to its ability to increase platelet cyclic GMP levels. 6. After exposure of rat aortic strips to supramaximal concentrations of GTN (550 microM), the vasorelaxant activity of CHF 2363 did not change, although that of GTN decreased about 55 fold. 7. It has been concluded that the new furoxan derivative CHF 2363 exerts a potent antiaggregating and vasorelaxant activity via NO release and increase of cyclic GMP levels. No in vitro cross tolerance between GTN and CHF 2363 was observed.
No takes yet. Share an insight, caveat, or question.
Civelli et al. (1996) studied this question. CHF 2363 vs. sodium nitroprusside and glyceryl trinitrate was evaluated on Platelet aggregation inhibition and vasorelaxant activity. CHF 2363 exerted potent antiaggregating and vasorelaxant activity via nitric oxide release and increased cyclic GMP levels, with no in vitro cross-tolerance with glyceryl trinitrate.
Synapse has enriched 10 related papers. Consider them for comparative context: